Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

34
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
78.42(c) 77.19(c) 77.08(c) 74.76(c) 74.48 Last
107 205 69 337 99 324 146 483 227 851 Volume
+3.43% -1.57% -0.14% -3.01% -0.37% Change
More quotes
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Sector
Biotechnology & Medical Research
Calendar
02/26 | 01:00amEarnings Release
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2015 65,5 M
EBIT 2015 -17,4 M
Net income 2015 -15,8 M
Finance 2015 187 M
Yield 2015 -
Sales 2016 71,4 M
EBIT 2016 28,3 M
Net income 2016 10,8 M
Finance 2016 200 M
Yield 2016 -
PER 2015 -
PER 2016 183,42
EV / Sales 2015 27,3x
EV / Sales 2016 24,9x
Capitalization 1 978 M
More Financials
Latest news on MORPHOSYS AG
02/26 MORPHOSYS : AG Reports Results for Fiscal Year 2014
02/20 MORPHOSYS : Invitation to Year End 2014 Conference Call of MorphoSys AG on 26 Fe..
02/10 MORPHOSYS : to Present at Leerink Global Healthcare Conference
01/29 MORPHOSYS : Patent Application Titled "Combinations and Uses Thereof" Published ..
01/08 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
2014 MORPHOSYS : AG: Corporate Calendar 2015
2014 MORPHOSYS : Announces Clinical Milestone in Oncology Program
2014 MORPHOSYS : and Xencor Report Final Results from Phase 1/2a Trial of Mor208
More news
Sector news Biotechnology & Medical Research - NEC
10:25a ISIS PHARMACEUTICALS : beats Street 4Q forecasts
09:44a ISIS PHARMACEUTICALS : Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx P..
09:31a ISIS PHARMACEUTICALS : Reports Financial Results and Highlights for 2014
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF